Suanfarma Suanfarma

X

Find Oclacitinib Maleate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

0

Listed Suppliers

Listed Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Oclacitinib Maleate
Also known as: 1208319-27-0, Oclacitinib (maleate), 1640292-55-2, Apoquel, Oclacitinib maleate [usan], Oclacitinib maleate(pf-03394197)
Molecular Formula
C19H27N5O6S
Molecular Weight
453.5  g/mol
InChI Key
VQIGDTLRBSNOBV-BTJKTKAUSA-N
FDA UNII
VON733L42A

1 2D Structure

Oclacitinib Maleate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(Z)-but-2-enedioic acid;N-methyl-1-[4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]methanesulfonamide
2.1.2 InChI
InChI=1S/C15H23N5O2S.C4H4O4/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15;5-3(6)1-2-4(7)8/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19);1-2H,(H,5,6)(H,7,8)/b;2-1-
2.1.3 InChI Key
VQIGDTLRBSNOBV-BTJKTKAUSA-N
2.1.4 Canonical SMILES
CNS(=O)(=O)CC1CCC(CC1)N(C)C2=NC=NC3=C2C=CN3.C(=CC(=O)O)C(=O)O
2.1.5 Isomeric SMILES
CNS(=O)(=O)CC1CCC(CC1)N(C)C2=NC=NC3=C2C=CN3.C(=C\C(=O)O)\C(=O)O
2.2 Other Identifiers
2.2.1 UNII
VON733L42A
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Apoquel

2. Oclacitinib

2.3.2 Depositor-Supplied Synonyms

1. 1208319-27-0

2. Oclacitinib (maleate)

3. 1640292-55-2

4. Apoquel

5. Oclacitinib Maleate [usan]

6. Oclacitinib Maleate(pf-03394197)

7. Pf-03394197-11

8. Von733l42a

9. Oclacitinib Maleate (usan)

10. (z)-but-2-enedioic Acid;n-methyl-1-[4-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]methanesulfonamide

11. N-methyl(trans-4-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclohexyl) Methanesulfonamide (2z)-2-butenedioate

12. Unii-von733l42a

13. Oclacitinib(maleate)

14. Pf-03394197 Maleate

15. Schembl260868

16. Chembl2105739

17. Oclacitinib Maleate [mi]

18. Schembl19205843

19. Amy19492

20. Ex-a3658

21. Hy-13577a

22. S8195

23. Ccg-269269

24. Cs-7611

25. Ac-32980

26. Bs-44681

27. D10142

28. D84061

29. Oclacitinib Maleate (ema Epar: Veterinary)

30. Pf 03394197-11

31. Q27291934

32. Cyclohexanemethanesulfonamide, N-methyl-4-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4- Ylamino)-, Trans-, (2z)-2-butenedioate (1:?)

33. N-methyl-1-((1r,4r)-4-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide Maleate

34. N-methyl-1-(trans-4-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide Maleate(1:x)

2.4 Create Date
2010-03-08
3 Chemical and Physical Properties
Molecular Weight 453.5 g/mol
Molecular Formula C19H27N5O6S
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count10
Rotatable Bond Count7
Exact Mass453.16820477 g/mol
Monoisotopic Mass453.16820477 g/mol
Topological Polar Surface Area174 Ų
Heavy Atom Count31
Formal Charge0
Complexity606
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

- Treatment of pruritus associated with allergic dermatitis in dogs.

- Treatment of clinical manifestations of atopic dermatitis in dogs.


5 Pharmacology and Biochemistry
5.1 ATC Code

QD11AH90


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY